Somewhat Positive Media Coverage Somewhat Unlikely to Impact Emergent Biosolutions (EBS) Share Price

News coverage about Emergent Biosolutions (NYSE:EBS) has been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Emergent Biosolutions earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.4151767076176 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have effected Accern Sentiment’s analysis:

A number of equities research analysts recently weighed in on EBS shares. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a research report on Wednesday, October 25th. Chardan Capital lifted their price objective on shares of Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. Finally, Goldman Sachs Group started coverage on shares of Emergent Biosolutions in a research note on Wednesday, January 24th. They issued a “neutral” rating and a $55.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Emergent Biosolutions currently has an average rating of “Hold” and a consensus target price of $51.00.

Emergent Biosolutions (NYSE:EBS) opened at $49.17 on Friday. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38. The company has a market cap of $2,430.00, a price-to-earnings ratio of 30.73, a price-to-earnings-growth ratio of 1.01 and a beta of 1.32. Emergent Biosolutions has a one year low of $27.94 and a one year high of $51.25.

In other Emergent Biosolutions news, Director Jerome M. Hauer sold 5,152 shares of Emergent Biosolutions stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $50.91, for a total value of $262,288.32. Following the transaction, the director now directly owns 23,797 shares in the company, valued at $1,211,505.27. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Zsolt Harsanyi sold 7,000 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $42.47, for a total transaction of $297,290.00. Following the transaction, the director now owns 37,077 shares in the company, valued at $1,574,660.19. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 125,722 shares of company stock worth $5,604,541. 16.50% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply